Cytek Biosciences (CTKB) Receivables - Net (2020 - 2026)

Cytek Biosciences' Receivables - Net history runs 7 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• Quarterly Receivables - Net fell 5.68% year-over-year to $51.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.9 million (down 5.68% YoY) and the FY2025 annual result came in at $62.5 million, up 3.17% from the prior year.
• Receivables - Net was $51.9 million for Q1 2026 at Cytek Biosciences, down from $62.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $62.5 million in Q4 2025 and bottomed at $30.4 million in Q1 2022.
• A 5-year average of $50.0 million and a median of $51.9 million in 2026 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net surged 64.19% — and 2024, when it retreated 10.04%.
• Cytek Biosciences' Receivables - Net stood at $48.9 million in 2022, then grew by 14.46% to $55.9 million in 2023, then climbed by 8.33% to $60.6 million in 2024, then grew by 3.17% to $62.5 million in 2025, then dropped by 16.97% to $51.9 million in 2026.
• Business Quant data shows CTKB's Receivables - Net at $51.9 million in Q1 2026, $62.5 million in Q4 2025, and $56.6 million in Q3 2025.